Avita Medical to Present at the B. Riley Investor Conference
May 17, 2012
OTC Disclosure News Service
Northridge, CA and Cambridge, UK –
AVITA MEDICAL TO PRESENT AT THE B. RILEY INVESTOR CONFERENCE
200 PRESENTING COMPANIES FROM DIVERSE INDUSTRY GROUPS
Northridge, CA and Cambridge, UK, 17 May 2012
—Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY), the regenerative medicine company, is pleased to announce that Dr William Dolphin, Avita Medical CEO, will be presenting at the B. Riley Co. 13th Annual Investor Conference taking place 21–23 May in Santa Monica, California. The B.Riley conference is a prestigious, invitation-only annual event bringing together a targeted audience of senior company executives and institutional, private equity and venture capital investors. The conference is expected to draw over 1,000 attendees, including senior company executives, institutional, private equity and venture capital investors
The conference will feature several tracks of presenting companies from a broad range of sectors. For additional information visit the conference website at http://brileyco.com/conferences_events/.
Additionally, Avita announced that it has retained MZ Group as its investor relations advisor to assist with corporate communications and global investor and shareholder outreach.
ABOUT AVITA MEDICAL LTD.
Avita Medical (www.avitamedical.com) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita’s patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient’s own skin. The company’s lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.